Stage IV Bladder Cancer AJCC v8 Clinical Trials

23 clinical trials for Stage IV Bladder Cancer AJCC v8 across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors — RECRUITING · PHASE2
• Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial — RECRUITING · PHASE1
• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology — RECRUITING · PHASE2
• Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors — RECRUITING · PHASE2
• Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial — RECRUITING · PHASE4
• An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers — RECRUITING · NA
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer — NOT_YET_RECRUITING · PHASE1
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study — ACTIVE_NOT_RECRUITING · PHASE3
• Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
• ARID1A and/or KDM6A Mutation and CXCL13 Expression — ACTIVE_NOT_RECRUITING · PHASE2
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes — COMPLETED
• Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate — ACTIVE_NOT_RECRUITING · PHASE1
• Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer — TERMINATED · PHASE2
• Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma — COMPLETED · PHASE2

Refine this search